Comparison · NCT00589914-sae
R092670 vs RISPERDAL CONSTA: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. R092670 vs RISPERDAL CONSTA: serious adverse events. Trial comparisons, record NCT00589914-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00589914-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0677 | 0.0503 | 0.0905 | wilson | |
| Risk in group 2 | 0.0477 | 0.0334 | 0.0677 | wilson | |
| Risk difference, group 1 minus group 2 | 0.02 | -0.00652 | 0.0469 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.42 | 0.894 | 2.25 | log | |
| Odds ratio, group 1 over group 2 | 1.45 | 0.888 | 2.36 | log | |
| Number needed to harm, for one more participant with a serious adverse event on R092670 than on RISPERDAL CONSTA | 50.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | R092670 | Double-blind period. Flexible dose of 50, 100 or 150 mg equivalent administered by i.m. injection every 4 weeks up to Week 9 (Day 64). | 41 | 606 | EG000 |
| Group 2 | RISPERDAL CONSTA | Double-blind period. Flexible dose of 25, 37.5 or 50 mg administered by i.m. injection every 2 weeks up to Week 11 (Day 78). | 29 | 608 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
- NCT number
- NCT00589914
- Phases
- PHASE3
- Conditions
- Schizophrenia
- Interventions
- RISPERDAL CONSTA, Paliperidone palmitate
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Results first posted
- 2011-10-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00589914?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00589914-sae